- New UK fund cornerstoned by £50 million investment from the British Business Bank, through its Enterprise Capital Funds (ECF) programme
- Epidarex Capital III UK LP will invest in new life science companies from emerging research hubs across the UK, including spinouts from highly regarded universities EDINBURGH, Scotland, June 22, 2020-- Epidarex Capital ("Epidarex"), a transatlantic life science venture firm, announces that it has closed Epidarex Capital III UK LP (the "Fund") at £102.1 million.